TECHNIQUES FOR DEMONSTRATION OF SPECIFICITY OF CIRCULATING ANTICOAGULANTS AGAINST ANTIHEMOPHILIC-FACTOR (FACTOR-VIII), WITH STUDIES OF 2 CASES POSSIBLY RELATED TO DIPHENYLHYDANTOIN THERAPY
- 1 January 1977
- journal article
- research article
- Vol. 49 (3) , 477-482
Abstract
Circulating anticoagulants against antihemophilic factor (AHF, factor VIII) sometimes seemed to inactivate other clotting factors as well. Measurements of the concentration of clotting factors in highly diluted plasma, or after neutralization of the anticoagulant with purified AHF, demonstrated the specific nature of the anticoagulant in a patient under treatment with diphenylhydantoin. A 2nd case in a patient treated with this agent, and with penicillin, an agent previously associated with the evolution of circulating anticoagulants, was also described.This publication has 6 references indexed in Scilit:
- IMMUNOLOGICAL EVIDENCE THAT PROPERTIES OF HUMAN ANTIHEMOPHILIC-FACTOR (FACTOR 8) ARE ATTRIBUTES OF A SINGLE MOLECULAR-SPECIES1976
- Severe Hypersensitivity to Diphenylhydantoin with Circulating Antibodies to the DrugAnnals of Internal Medicine, 1975
- HETEROGENEITY OF HUMAN CIRCULATING ANTICOAGULANTS AGAINST ANTIHEMOPHILIC-FACTOR (FACTOR 8)1975
- The Development of Hodgkin’s Disease and Lymphoma during Anticonvulsant TherapyBlood, 1966
- Combined Factor VIII and IX Inhibitors in a GirlThrombosis and Haemostasis, 1966
- Dilantin-induced serum sicknessThe American Journal of Medicine, 1963